1. Patients who are planning to start hemodialysis or to have a renal transplant within 24 weeks after enrollment,

2. Patients with a history of treatment with ESA except the ones who were treated temporarily more than 12 weeks before the enrollment,

3. Patients with malignant tumor, hematological disease, or hemorrhagic lesions,

4. Patients with hypersensitivity to ESA or any ingredient thereof,

5. Pregnant, lactating or possibly pregnant women or those who wish to become pregnant during the study period,

6. Patients who are participating in other clinical study,

Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents